Merck & Co Inc Reports 3% Increase in Stock Price
Merck & Co Inc’s stock price has increased by nearly 3% in recent trading. This increase is attributed to positive news from regulatory bodies, including the US FDA’s approval of its RSV antibody for infants and its cancer treatment, KEYTRUDA.
The FDA’s approval of KEYTRUDA for the treatment of certain head and neck cancers is a significant milestone for the company. This approval is a result of KEYTRUDA’s demonstrated efficacy in clinical trials.
Recent Market Volatility
Despite some volatility in the market, driven by global events such as the Israeli airstrike on Iranian nuclear facilities, Merck & Co Inc’s stock price remains relatively stable.
Key Developments
- US FDA approval of RSV antibody for infants
- US FDA approval of KEYTRUDA for the treatment of certain head and neck cancers
- 3% increase in Merck & Co Inc’s stock price in recent trading